Search / Trial NCT06612567

Normal Variants and Pitfalls of 18F_FDG PET/CT in Pediatric Oncology

Launched by ASSIUT UNIVERSITY · Sep 22, 2024

Trial Information

Current as of December 21, 2024

Not yet recruiting

Keywords

ClinConnect Summary

Although pediatric cancer is relatively rare compared with adult cancer, it is the second most common cause of death, after injury in children and adolescents. lymphoma, Leukemia, and brain cancer, account for more than half of pediatric cancers, followed by neuroblastoma, soft-tissue sarcomas, Wilms tumors, and bone tumors .

18Fluorine-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) plays an important role, staging, restaging, response to treatment in childhood malignancies. PET-only examinations have been replaced by hybrid systems in the recent dec...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • All Pediatric Cancer patients referred to nuclear medicine unit to do 18F-FDG PET/CT study.
  • All patients \> or = 18 years.
  • Exclusion Criteria:
  • Severely ill patients. Patients with glucose level \< 200 mg/dl.

About Assiut University

Assiut University, a prominent academic institution located in Egypt, is dedicated to advancing medical research and clinical trials that enhance healthcare outcomes. With a strong emphasis on innovation and collaboration, the university engages in a wide array of clinical studies across various disciplines, aiming to contribute valuable insights into disease prevention, diagnosis, and treatment. Assiut University's commitment to ethical research practices and rigorous scientific methodology ensures the integrity and reliability of its clinical trials, ultimately benefiting both the local community and the global medical landscape.

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0